Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · Lancet · 2026-10-29

In 5 trials (110,933 presentations) of suspected heart attack, the 0/1 h troponin pathway did not clearly differ from 0/3 h on 30-day death or new type 1 MI (0.8% vs 1.0%), and did not shorten emergency department stay.

Meta-analysisn = 110,933 presentations
Boeddinghaus et al. Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials
Cardiology · Lancet · 2026-09-30

In 2749 adults with type 2 diabetes and high cardiovascular risk, oral orforglipron was non-inferior to insulin glargine for MACE-4 over 2 years (4.2% vs 5.0%; HR 0.84, 95% CI 0.59-1.20). GI adverse events were more common (62% vs 14%).

RCTn = 2,749
Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Cardiology · Lancet · 2026-08-29

In 67,624 ED presentations with suspected MI at 19 hospitals, switching from a 0/3 h to a 0/1 h troponin pathway was non-inferior for 30-day death or type 1 MI (1.1% vs 1.2%; aOR 0.93) but did not shorten ED stay (median 309 vs 309 min; p=0.65).

RCTn = 67,624 patient presentations
Boeddinghaus et al. Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial
Cardiology · Circulation · 2026-08-18

In a prespecified secondary analysis of SELECT (17,604 adults with CVD and overweight/obesity, no diabetes), semaglutide cut hsCRP by 37.8% at 104 weeks, including without weight loss, and cut MACE vs placebo across hsCRP subgroups. Higher baseline hsCRP predicted MACE.

Secondary analysisn = 17,604
Plutzky et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.